AnaptysBio Correlations
ANAB Stock | USD 21.50 0.90 4.02% |
The current 90-days correlation between AnaptysBio and Kura Oncology is 0.13 (i.e., Average diversification). The correlation of AnaptysBio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
AnaptysBio Correlation With Market
Weak diversification
The correlation between AnaptysBio and DJI is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding AnaptysBio and DJI in the same portfolio, assuming nothing else is changed.
AnaptysBio |
Moving together with AnaptysBio Stock
0.68 | ME | 23Andme Holding | PairCorr |
0.7 | DTIL | Precision BioSciences | PairCorr |
0.71 | VINC | Vincerx Pharma | PairCorr |
0.69 | EDIT | Editas Medicine | PairCorr |
0.88 | EDSA | Edesa Biotech Fiscal Year End 20th of December 2024 | PairCorr |
Moving against AnaptysBio Stock
0.72 | DRUG | Bright Minds Biosciences | PairCorr |
0.7 | SABSW | SAB Biotherapeutics | PairCorr |
0.67 | VERA | Vera Therapeutics | PairCorr |
0.64 | VCYT | Veracyte | PairCorr |
0.42 | VERV | Verve Therapeutics Sell-off Trend | PairCorr |
0.35 | DSGN | Design Therapeutics | PairCorr |
0.33 | VIGL | Vigil Neuroscience | PairCorr |
0.82 | VSTM | Verastem | PairCorr |
0.74 | VRNA | Verona Pharma PLC | PairCorr |
0.43 | VRDN | Viridian Therapeutics | PairCorr |
Related Correlations Analysis
-0.34 | -0.35 | 0.03 | 0.29 | DCPH | ||
-0.34 | 0.54 | -0.6 | -0.63 | CRNX | ||
-0.35 | 0.54 | -0.27 | -0.44 | RYTM | ||
0.03 | -0.6 | -0.27 | 0.74 | KURA | ||
0.29 | -0.63 | -0.44 | 0.74 | CTMX | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between AnaptysBio Stock performing well and AnaptysBio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AnaptysBio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
DCPH | 1.66 | (0.17) | 0.00 | 1.08 | 0.00 | 3.27 | 9.66 | |||
CRNX | 1.61 | 0.13 | 0.06 | 0.31 | 1.74 | 3.67 | 10.50 | |||
RYTM | 2.46 | 0.26 | 0.17 | 0.28 | 2.15 | 7.37 | 13.98 | |||
KURA | 1.64 | (0.17) | 0.00 | (0.02) | 0.00 | 4.52 | 8.67 | |||
CTMX | 2.48 | (0.32) | 0.00 | (0.16) | 0.00 | 5.00 | 17.21 |
AnaptysBio Corporate Management
Martin Dahl | Senior Research | Profile | |
Monique Silva | Senior Affairs | Profile | |
James MD | Advisor | Profile | |
Beth Mueller | Senior Resources | Profile | |
Priya Raina | Senior Operations | Profile | |
Eric Loumeau | General Counsel | Profile | |
FAAD MBA | Chief Officer | Profile |